安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Sun Pharmaceutical Industries Ltd. - Moneycontrol
Sun Pharma Standalone December 2024 Net Sales at Rs 6,191 81 crore, up 22 04% Y-o-Y 31 01 2025 Sun Pharma Q3 net profit rises 15% to Rs 2,903 4 crore, meets estimate; Rs 10 5 dividend declared
- Creating Lasting Value - Sun Pharma
Gross margin= (Net Sales –Material Cost) Net Sales * 100 #Top 9 Indian Pharma companies include Cipla, Dr Reddy’s, Aurobindo, Zydus Lifesciences, Torrent, Alkem Labs, Lupin, Ipca and Glenmark Best-in-class profitability
- Sun Pharma vs Divi’s Lab vs Dr. Reddy’s Lab vs Cipla
Sun Pharma recently reported its financial results, showing a notable increase in its net profit and revenue For the quarter ending in December 2023, Sun Pharma recorded a consolidated profit after tax of 25 24 billion rupees, exceeding analysts’ expectations
- Sun Pharma To Dr. Reddys Q4 Preview: Indian Pharmas To See Strong Q4 . . .
As Indian pharmaceuticals commence announcement of fourth quarter earnings, the aggregate picture suggests a 16% year-on-year sales growth for a cohort of key players — Sun Pharmaceutical Industries Ltd , Cipla Ltd , Dr Reddy's Laboratories Ltd, Torrent Pharma, and JB Chemicals Pharmaceuticals
- FINANCIAL PERFORMANCE ANALYIS OF CIPLA SUN PHARMA- A COMPARITIVE STUDY
performance of gross profit and operating profit While measuring the gross profit of SUN PHARMA the GP margin was at 94 92% whereas for CIPLA it is 75 06%, this is mainly due to increase in overall cost, however the ROCE of SUN PHARMA is 13 15% in 2021, whereas it 5 4% for CIPLA
- Sun Pharma Q4 FY25: Profit May Rise 18% YoY to ₹3,070 Cr - Value Research
Sun Pharma remains the largest among peers, both in terms of revenue and profit Dr Reddy's shows the fastest revenue growth due to biosimilar launches and portfolio gains Cipla sees moderate growth driven by strength in India and South Africa
- Cipla Vs Dr. Reddy’s Laboratories – Financials, Future Plans More
Upon comparing Revenue Profit figures Dr Reddy’s significantly outperforms Cipla On a 5 5-year term period, Cipla is able to maintain a Revenue growth of 9% CAGR while Dr Reddy maintains 13% CAGR Profitability of Cipla Dr Reddy’s grew by 16% and 23% on a 5 Year CAGR
- Annual Reports Presentations | Sun Pharmaceutical Industries Limited
At Sun, we remain committed to creating long term value for our shareholders In line with this philosophy, we will continue to focus on performance and producing consistent returns
|
|
|